1. Home
  2. GGR vs PMN Comparison

GGR vs PMN Comparison

Compare GGR & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gogoro Inc.

GGR

Gogoro Inc.

N/A

Current Price

$2.82

Market Cap

83.3M

ML Signal

N/A

Logo ProMIS Neurosciences Inc. (ON)

PMN

ProMIS Neurosciences Inc. (ON)

N/A

Current Price

$3.76

Market Cap

84.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GGR
PMN
Founded
2011
2004
Country
Taiwan
Canada
Employees
N/A
N/A
Industry
Auto Manufacturing
Pharmaceuticals and Biotechnology
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
83.3M
84.1M
IPO Year
2021
2022

Fundamental Metrics

Financial Performance
Metric
GGR
PMN
Price
$2.82
$3.76
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
★ $42.27
AVG Volume (30 Days)
7.3K
★ 362.7K
Earning Date
11-11-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$4.97
N/A
Revenue Next Year
$6.11
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.02
$0.29
52 Week High
$5.43
$27.40

Technical Indicators

Market Signals
Indicator
GGR
PMN
Relative Strength Index (RSI) 42.57 31.77
Support Level $2.51 $2.78
Resistance Level $3.32 $15.05
Average True Range (ATR) 0.14 1.21
MACD -0.03 -0.19
Stochastic Oscillator 18.07 10.75

Price Performance

Historical Comparison
GGR
PMN

About GGR Gogoro Inc.

Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.

About PMN ProMIS Neurosciences Inc. (ON)

ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.

Share on Social Networks: